Attention Deficit Hyperactivity Disorder Market Size, Share, Growth, Trends | Report 2023-2032
The global attention deficit hyperactivity disorder market was surpassed at USD 13.27 billion in 2022 and is expected to hit around USD 20.06 billion by 2032, growing at a CAGR of 4.22% from 2023 to 2032.
Key Pointers
| Report Coverage | Details |
| Market Size in 2022 | USD 13.27 billion |
| Revenue Forecast by 2032 | USD 20.06 billion |
| Growth rate from 2023 to 2032 | CAGR of 4.22% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies Covered | Novartis AG, Eli Lilly and Company, Johnson & Johnson Services, Inc., Lupin, Takeda Pharmaceutical Company Limited, Mallinckrodt plc., Pfizer, Inc., Purdue Pharma L.P., NEOS Therapeutics Inc., Supernus Pharmaceuticals Inc. |
The rising prevalence of ADHD across the globe is expected to contribute to market growth. According to the ADHD Institute, the estimated prevalence of the disease ranges from 0.1% to 8.1% in children and adolescents worldwide. The mean prevalence of attention deficit hyperactivity disorder in adults aged 18 to 45 years is approximately 2.8% in Asia, Europe, North America, and MEA.
Extensive research studies conducted by organizations to evaluate the safety and efficacy of drugs in patients with attention deficit hyperactivity disorder are expected to drive market growth soon. The positive outcomes of these studies open new opportunities in the market. According to the study published by Boston Children's Hospital in 2021, alpha-2-adrenergic agonists such as guanfacine & clonidine can be effective in lowering the symptoms of disease in children. Further, it showed that these medications have minimum side effects compared to other stimulants like amphetamines (Adderall, Vyvanse) and methylphenidate (Ritalin, Concerta), which are often used as first-line treatment for attention deficit hyperactivity disorder.
Increasing initiatives undertaken by key players for the promotion of products may open new avenues for business. For instance, Eli Lilly and Company under the Lilly Cares Foundations' patient assistance program provides Strattera (Atomoxetine) free of cost for one year to eligible patients for their treatments. The eligibility of the program includes U.S.-based non-insured patients with a physician-prescribed prescription. This program may boost the prescription rate for Strattera by encouraging physicians to prescribe this product to patients.
Various factors restraining the growth of the market are short-term and long-term adverse effects such as permanent damage of blood vessels of the brain and heart, lung, liver, & kidney as well as increased blood pressure leading to heart attack, stroke, and death. According to a study published by the University of Toronto in October 2021, the incidence of heart attack and stroke increased by 40% and 30% in ADHD patients after consumption of Ritalin and other stimulant drugs during an initial 30 days period.
Attention Deficit Hyperactivity Disorder Market Segmentations:
By Drug Type
By Demographics
By Distribution Channel
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Attention Deficit Hyperactivity Disorder Market
5.1. COVID-19 Landscape: Attention Deficit Hyperactivity Disorder Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Attention Deficit Hyperactivity Disorder Market, By Drug Type
8.1. Attention Deficit Hyperactivity Disorder Market, by Drug Type, 2023-2032
8.1.1 Stimulants
8.1.1.1. Market Revenue and Forecast (2019-2032)
8.1.2. Non-stimulants
8.1.2.1. Market Revenue and Forecast (2019-2032)
Chapter 9. Global Attention Deficit Hyperactivity Disorder Market, By Demographics
9.1. Attention Deficit Hyperactivity Disorder Market, by Demographics, 2023-2032
9.1.1. Children (2 to 17 years of age)
9.1.1.1. Market Revenue and Forecast (2019-2032)
9.1.2. Adults
9.1.2.1. Market Revenue and Forecast (2019-2032)
Chapter 10. Global Attention Deficit Hyperactivity Disorder Market, By Distribution Channel
10.1. Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2023-2032
10.1.1. Retail Pharmacy
10.1.1.1. Market Revenue and Forecast (2019-2032)
10.1.2. Hospital Pharmacy
10.1.2.1. Market Revenue and Forecast (2019-2032)
Chapter 11. Global Attention Deficit Hyperactivity Disorder Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Drug Type (2019-2032)
11.1.2. Market Revenue and Forecast, by Demographics (2019-2032)
11.1.3. Market Revenue and Forecast, by Distribution Channel (2019-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Drug Type (2019-2032)
11.1.4.2. Market Revenue and Forecast, by Demographics (2019-2032)
11.1.4.3. Market Revenue and Forecast, by Distribution Channel (2019-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Drug Type (2019-2032)
11.1.5.2. Market Revenue and Forecast, by Demographics (2019-2032)
11.1.5.3. Market Revenue and Forecast, by Distribution Channel (2019-2032)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Drug Type (2019-2032)
11.2.2. Market Revenue and Forecast, by Demographics (2019-2032)
11.2.3. Market Revenue and Forecast, by Distribution Channel (2019-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Drug Type (2019-2032)
11.2.4.2. Market Revenue and Forecast, by Demographics (2019-2032)
11.2.4.3. Market Revenue and Forecast, by Distribution Channel (2019-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Drug Type (2019-2032)
11.2.5.2. Market Revenue and Forecast, by Demographics (2019-2032)
11.2.5.3. Market Revenue and Forecast, by Distribution Channel (2019-2032)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Drug Type (2019-2032)
11.2.6.2. Market Revenue and Forecast, by Demographics (2019-2032)
11.2.6.3. Market Revenue and Forecast, by Distribution Channel (2019-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Drug Type (2019-2032)
11.2.7.2. Market Revenue and Forecast, by Demographics (2019-2032)
11.2.7.3. Market Revenue and Forecast, by Distribution Channel (2019-2032)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Drug Type (2019-2032)
11.3.2. Market Revenue and Forecast, by Demographics (2019-2032)
11.3.3. Market Revenue and Forecast, by Distribution Channel (2019-2032)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Drug Type (2019-2032)
11.3.4.2. Market Revenue and Forecast, by Demographics (2019-2032)
11.3.4.3. Market Revenue and Forecast, by Distribution Channel (2019-2032)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Drug Type (2019-2032)
11.3.5.2. Market Revenue and Forecast, by Demographics (2019-2032)
11.3.5.3. Market Revenue and Forecast, by Distribution Channel (2019-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Drug Type (2019-2032)
11.3.6.2. Market Revenue and Forecast, by Demographics (2019-2032)
11.3.6.3. Market Revenue and Forecast, by Distribution Channel (2019-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Drug Type (2019-2032)
11.3.7.2. Market Revenue and Forecast, by Demographics (2019-2032)
11.3.7.3. Market Revenue and Forecast, by Distribution Channel (2019-2032)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Drug Type (2019-2032)
11.4.2. Market Revenue and Forecast, by Demographics (2019-2032)
11.4.3. Market Revenue and Forecast, by Distribution Channel (2019-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Drug Type (2019-2032)
11.4.4.2. Market Revenue and Forecast, by Demographics (2019-2032)
11.4.4.3. Market Revenue and Forecast, by Distribution Channel (2019-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Drug Type (2019-2032)
11.4.5.2. Market Revenue and Forecast, by Demographics (2019-2032)
11.4.5.3. Market Revenue and Forecast, by Distribution Channel (2019-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Drug Type (2019-2032)
11.4.6.2. Market Revenue and Forecast, by Demographics (2019-2032)
11.4.6.3. Market Revenue and Forecast, by Distribution Channel (2019-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Drug Type (2019-2032)
11.4.7.2. Market Revenue and Forecast, by Demographics (2019-2032)
11.4.7.3. Market Revenue and Forecast, by Distribution Channel (2019-2032)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Drug Type (2019-2032)
11.5.2. Market Revenue and Forecast, by Demographics (2019-2032)
11.5.3. Market Revenue and Forecast, by Distribution Channel (2019-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Drug Type (2019-2032)
11.5.4.2. Market Revenue and Forecast, by Demographics (2019-2032)
11.5.4.3. Market Revenue and Forecast, by Distribution Channel (2019-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Drug Type (2019-2032)
11.5.5.2. Market Revenue and Forecast, by Demographics (2019-2032)
11.5.5.3. Market Revenue and Forecast, by Distribution Channel (2019-2032)
Chapter 12. Company Profiles
12.1. Novartis AG
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Eli Lilly and Company
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Johnson & Johnson Services, Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Lupin
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Takeda Pharmaceutical Company Limited
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Mallinckrodt plc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Pfizer, Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Purdue Pharma L.P.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. NEOS Therapeutics Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Supernus Pharmaceuticals Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers